quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:09:20·44d
INSIDERFiling
ANI Pharmaceuticals Inc. logo

PRESIDENT & CEO Lalwani Nikhil covered exercise/tax liability with 17,060 shares, decreasing direct ownership by 4% to 404,889 units (SEC Form 4)

ANIP· ANI Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ANIP
    ANI Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Jul 10UpdateH.C. Wainwright$84.00
  • Mar 14UpdateJefferies$80.00
  • Mar 12UpdateAnalyst$85.00
  • Dec 11UpdateLeerink Partners$80.00
  • Oct 11UpdatePiper Sandler$68.00
  • Mar 15UpdateCapitalOne$80.00

Related

  • PR3d
    ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
  • INSIDER10d
    SEC Form 4 filed by Cook Meredith
  • PR10d
    ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
  • SEC14d
    SEC Form DEFA14A filed by ANI Pharmaceuticals Inc.
  • SEC14d
    SEC Form DEF 14A filed by ANI Pharmaceuticals Inc.
  • PR15d
    ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
  • SEC16d
    ANI Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
  • PR16d
    ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022